Why it matters: Although the 2010 NICE Technology Appraisal recommends dipyridamole for the prevention of further occlusive events in patients who have had a Transient Ischaemic Attack (TIA), 2016 guidance from the Royal College of Physicians states: the Working Party considers that a unified approach to the treatment of TIA and ischaemic stroke is more appropriate. Whilst clopidogrel does not have a licence for use after TIA, the Working Party considers that the benefits of recommending this drug first-line outweigh any disadvantages. For long-term vascular prevention in people with ischaemic stroke or TIA without paroxysmal or permanent atrial fibrillation: - clopidogrel 75mg daily should be the standard antithrombotic treatment; - aspirin 75 mg daily with modified-release dipyridamole 200 mg twice daily should be used for those who are unable to tolerate clopidogrel; - aspirin 75mg daily should be used if both clopidogrel and modified-release dipyridamole are contraindicated or not tolerated; - modified-release dipyridamole 200 mg twice daily should be used if both clopidogrel and aspirin are contraindicated or not tolerated.
Description: Total items for dipyridamole (as dipyridamole or dipyridamole/aspirin combination), as a proportion of total items of dipyridamole, dipyridamole/aspirin combination and clopidogrel
Sub-ICB Locations are ordered by mean percentile over the past six months. Each chart shows the results for the individual Sub-ICB Location, plus deciles across all Sub-ICB Locations in the NHS in England.